Table 1 Clinical and laboratory features of patients with APS and SLE, and healthy controls
Diagnosis | APS (n = 59) | SLE/APL+ (n = 60) | SLE/APL- (n = 46) | HC (n = 40) |
|---|---|---|---|---|
Age, mean, years ± SD | 46 ± 12 | 37 ± 11 | 36 ± 13 | 31 ± 8 |
Sex, male/female, n | 10/49 | 1/59 | 6/40 | 19/21 |
VT only, n (%) | 31 (52) | 5 (8) | 10 (21) | 0 |
PM only, n (%) | 13 (22) | 6 (10)* | 10 (25)* | 0 |
VT + PM, n (%) | 12 (20) | 1 (2)* | 3 (7.5)* | 0 |
CAPS, n (%) | 3 (5) | 0 | 0 | 0 |
Other ARD, n (%) | SLE 25 (42) | 0 | 0 | 0 |
aCL, mean GPL units | 59.7 | 15.2 | 13 | 9 |
Anti-β2GPI, mean AU | 35,5 | 22 | 4 | 3 |
LA, n (%) | 46 (78) | 31 (51.7) | 0 | 0 |
Anti-Thr+, n (%) | 21 (35.6) | 36 (60) | 23 (50) | 2 (5) |
Anti-FVIIa+, n (%) | 5 (8.5) | 7 (11.7) | 9 (19.6) | 2 (5) |
Anti-FXa+, n (%) | 20 (33.9) | 29 (48.3) | 23 (50) | 0 |
Anti-PS/Xa+, n (%) | 8 (13.6) | 20 (33.3) | 15 (32.6) | 1 (2.5) |